Abingdon, United Kingdom

James Lindsay Carr

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 9.2

ph-index = 1


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Innovations of James Lindsay Carr

Introduction

James Lindsay Carr is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of pharmaceutical sciences, particularly in the area of integrated stress response pathways. With a total of 3 patents, Carr's work has the potential to impact the treatment of various diseases and disorders.

Latest Patents

Carr's latest patents focus on modulators of the integrated stress response pathway. The first patent describes compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers, or stereoisomers thereof. These compounds are intended for use as medicaments in treating and preventing diseases associated with the integrated stress response. The second patent also relates to similar compounds and their pharmaceutical compositions, emphasizing their therapeutic applications.

Career Highlights

Throughout his career, Carr has worked with prominent companies in the pharmaceutical industry, including Evotec International GmbH and Bayer Aktiengesellschaft. His experience in these organizations has contributed to his expertise in developing innovative solutions for medical challenges.

Collaborations

Carr has collaborated with notable colleagues such as Holly Atton and Christopher John Brown. These partnerships have likely enhanced his research and development efforts in the field.

Conclusion

James Lindsay Carr's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…